N4 Pharma PLC Patent Grant (2078A)

TIDMN4P

RNS Number : 2078A

N4 Pharma PLC

19 January 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

Patent Grant

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce that the University of Queensland has informed the Company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec(R) in India.

The granted patent in India is for a composition of matter patent for the particle itself as well as the manufacturing process relating to how the particle is made and matches the patents granted in the USA, Canada, Europe, Japan, Australia and China .

Nigel Theobald, Chief Executive Officer of the Company, commented:

"The granting of this patent is a further indication of the strength of the intellectual property we have licensed from the University of Queensland and we now have all of the major global territories with granted patents for Nuvec(R)."

For more information please contact:

 
 N4 Pharma plc 
  Nigel Theobald, CEO                        Via N4 Pharma Investor 
  Luke Cairns, Executive Director            Hub 
 
  Engage with us directly at N4 Pharma 
  Investor Hub                               Sign up at investors.n4pharma.com 
 
  To hear more, visit                        https://investors.n4pharma.com/link/0y5nKe 
 SP Angel Corporate Finance LLP            Tel: +44(0)20 3470 0470 
  Nominated Adviser and Joint Broker 
  Matthew Johnson/Caroline Rowe/Kasia 
  Brzozowska (Corporate Finance) 
  Vadim Alexandre/Abigail Wayne/Rob Rees 
  (Corporate Broking) 
                                          --------------------------------------------- 
 Turner Pope Investments (TPI) Limited     Tel: +44(0)20 3657 0050 
  Joint Broker 
  Andy Thacker 
  James Pope 
                                          --------------------------------------------- 
 IFC Advisory Ltd                          Tel: +44(0)20 3934 6630 
  Financial PR 
  Graham Herring 
  Zach Cohen 
                                          ---------------------------------------------

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec(R) and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.

N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec(R) or Liptide(R) as the delivery vehicle for these products. As these products progress through pre--clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDVLFFZFLFBBB

(END) Dow Jones Newswires

January 19, 2024 02:00 ET (07:00 GMT)

N4 Pharma (AQSE:N4P.GB)
過去株価チャート
から 11 2024 まで 12 2024